About Emergent

Emergent BioSolutions Inc. is a profitable, multinational biopharmaceutical company dedicated to one simple mission -to protect life. We develop, manufacture and commercialize imune-related biologics, consisting of vaccines and therapeutics that assist the body's immune system to prevent or treat infectious and other life-threatening diseases. Our marketed product, BioThrax^® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax infection.

Our employees pursue innovative ways of directing the immune system to prevent and treat life-threatening diseases. Whether it is developing vaccines and therapeutics that hold the promise of a better life for millions of adults and children or providing the world’s only FDA-approved anthrax vaccine to protect against the threat of bioterrorism, we are passionate in our mission.

We are a biopharmaceutical company that is:

Focused - we focus on product development, from proof-of-concept to commercialization. Our approach is to continuously evaluate and prioritize our development programs to ensure that we advance those product candidates that hold the greatest promise.

Balanced - we develop both vaccines and therapeutics serving multiple markets.

Collaborative - we aim to establish non-dilutive partnerships with governmental and non-governmental organizations in the US and abroad to leverage our investment in the development of our own product candidates.

Acquisitive - we pursue the licensure and acquisition of products and product candidates that leverage our existing capabilities and expand our pipeline.

Profitable - we manage our business in a fiscally responsible manner. This has helped us achieve a track record of financial success that has enabled us to fund our pipeline development.